formation of syntiron

Realizing the potential for Epitopix intellectual property in combating human disease, Epitopix and WPC formed Syntiron to adapt the Epitopix SRP technology to the development of human vaccines. Based in St. Paul, Syntiron leases 3 labs in a building owned by the University of Minnesota.


Apply Now